Patient Preferences on Clinical Decision Making in Multiple Myeloma
Our findings show that many patients choose not to receive treatments that improve PFS if they do not positively affect OS and lead to substantial clinical, financial, and/or time toxicities.
Authors
- Rajshekhar Chakraborty (ORCID: https://orcid.org/0000-0001-7336-3003)
- Jay R. Hydren
- Ghulam Rehman Mohyuddin (ORCID: https://orcid.org/0000-0001-6464-783X)
- Katherine Berger (ORCID: https://orcid.org/0000-0002-8892-2135)
- Douglas W. Sborov (ORCID: https://orcid.org/0000-0003-4268-2698)
- Amandeep Godara (ORCID: https://orcid.org/0000-0003-1943-4442)
- Brian McClune (ORCID: https://orcid.org/0000-0003-0007-4192)
- Jorge Arturo Hurtado Martínez (ORCID: https://orcid.org/0000-0002-4503-1690)
- Edward R. Scheffer Cliff (ORCID: https://orcid.org/0000-0001-5977-907X)
- Christopher M. Booth (ORCID: https://orcid.org/0000-0002-1353-3653)
- Mason S. Barnes
- Ryan Winborg
Institutions
- Brigham Young University (US)
- Brigham and Women's Hospital (US)
- The Royal Melbourne Hospital (AU)
- Queen's University (CA)
- Columbia University Irving Medical Center (US)
- Peter MacCallum Cancer Centre (AU)
- Huntsman Cancer Institute (US)
- Agência Nacional de Energia Elétrica (BR)
- Patient Advocate Foundation (US)
- Columbia University (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1200/op-25-00322
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54